Cancer Research Consortium of West Michigan

Breast Clinical Trials

Cancer clinical trials are research studies for developing better ways of detecting, treating, and eventually preventing cancer. By taking part in a clinical trial, you are among the first to receive new research treatments before they are widely available. Your participation in a clinical trial will influence the future direction of cancer care.

If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.

Provided drugs are underlined

For more information, call the CRCWM Main office at 616.391.1230 or 800.336.5079

Narrow List by Age:


Cancer Type: Triple-Negative Invasive Breast Cancer
Research Base: NRG
Protocol: NRG BR003

NRG BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

Cancer Type: Node Positive Her2 Negative Breast Cancer
Research Base: Alliance
Protocol: Alliance A011502


Cancer Type: Breast Cancer
Research Base: Wake Forest
Protocol: WF 97116

WF 97116:  A Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors with Cognitive Impairment

Cancer Type: ER(+) NeoAdjuvant
Research Base: Alliance
Protocol: Alliance A011106

A011106: ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: a phase III study

Cancer Type: HER2 negative early breast Cancer
Research Base: AFT
Protocol: AFT-5 Pallas
PALbociclib CoLlaborative Adjuvant Study:
A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer  
Cancer Type: ER/PgR Any; Her2 Negative; Post Adjuvant
Research Base: NRG
Protocol: NSABP B-55

NSABP B55: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Center Phase III Study. Olaparib vs Placebo. Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy. 

Cancer Type: Triple-Negative Basal-Like Breast Cancer
Research Base: ECOG-ACRIN
Protocol: EA1131

ECOG EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy vs Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Cancer Type: High-Risk, ER/PR+ and HER2/neu -
Research Base: SWOG
Protocol: SWOG S1207

SWOG S1207: Phase III randomized trial. Endocrine Therapy + Everolimus/Placebo. High-risk hormone receptor positive and HER2/NEU negative breast cancer. Staging I-III.

Cancer Type: RT for (+)Node?Neo Chemo f/b surg?(-)Node
Research Base: NRG
Protocol: NSABP B-51

NSABP B-51: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy. 

Cancer Type: Triple(-); ypT1or ypN(+)
Research Base: SWOG
Protocol: SWOG S1418

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy

Cancer Type: ER/PR(+); Her2 Negative
Research Base: CTSU
Protocol: CTSU E2112

CTSU E2112: Phase III Trial;  Endocrine Therapy Plus Entinostat/Placebo; Patients with Hormone Receptor-Positive Advanced Breast Cancer

Cancer Type: Mets; Triple Negative
Research Base: SWOG
Protocol: SWOG S1416

Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer

Cancer Type: HER2 Positive Breast Cancer w/Brain Mets
Research Base: NRG
Protocol: RTOG 1119

RTOG 1119: Phase II Randomized Study. WBRT +/- Lapatinib in patients with brain metastasis from HER2-Positive breast cancer. Stage IV.

Cancer Type: Metastatic Breast Cancer (MBC)
Research Base: Sarah Cannon
Protocol: SCRI BRE 203

SCRI BRE 203: A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR).  

Cancer Type: Locally Recurrent or Mets; 1st or 2nd Line
Research Base: ACCRU
Protocol: ACCRU RU011201I

ACCRU RU011201I A Randomized Phase III Trial of Eribulin vs Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer. Not available at Lakeland HealthCare
Staging: 1st or 2nd Line, Locally Recurrent or Metastatic Stage IV or Stage IIIC Not Amenable To Local Therapy, HER2(-). Treatment: Eribulin vs Paclitaxel

Cancer Type: Breast cancer
Research Base: Alliance
Protocol: Alliance A011401

Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

Cancer Type: ER/PR+ Breast Cancer
Research Base: CTSU
Protocol: CTSU E1Z11

CTSU E1Z11: A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS) Specimen Processing Lab 2/24/14. Stage I - III Adenocarcinoma of the breast. Patients must be ER/PR+. Treatment: Anastrozole. 

Cancer Type: Breast Cancer
Research Base: Alliance
Protocol: Alliance A011104

Alliance A011104: Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer

Cancer Type: Stage I-III Breast or lymphoma
Research Base: Wake Forest
Protocol: WF 98213 - PREVENT

Preventing Anthracycline Cardiovascular Toxicity with Statins (PREVENT) - Newly diagnosed Stage I-III breast cancer (including inflammatory and newly diagnosed recurrent breast cancer) or lymphoma with a > 2 year life expectancy. Statin/atorvastatin or Placebo